MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Biology grad helping develop breakthrough malaria vaccine
A long sought-after vaccine for malaria, a disease that killed 660,000 people and infected more than 200 million others in 2010, is one huge step closer, thanks to a promising breakthrough developed in part by Peter Billingsley, PhD’85 (Biology).
Sanaria is a proud sponsor of Frontiers in Science and Medicine Day 2013
600 participated in fifth annual Frontiers in Science and Medicine Day.
Dr. Hoffman vs. the Mosquito
A Rockville scientist has spent 30 years struggling to eradicate malaria, the deadly insect-borne disease that has outwitted generations of medical researchers. Experts have long called his vaccine a fantasy. Now he has one last chance to prove himself.
Malaria specialists meeting in Durban
The Minister of Health, together with the heads of the various departments of the ministry and the institutions collaborating in the fight against the disease in Equatorial Guinea, attended the Sixth Pan-African Malaria Conference, held in Durban (South Africa).
Sanaria CEO, Dr. Stephen L. Hoffman answers questions about the SANARIA PfSPZ Vaccine on Reddit’s AMA
Update: The Reddit AMA is now closed but you can go back and read it in the archive.
Sanaria’s Malaria Vaccine Yields Unprecedented Protection In Phase 1 Clinical Trial
Results of a phase I clinical trial of the Sanaria® PfSPZ Vaccine to combat malaria, published today in the online issue of Science magazine, show that the vaccine provided complete protection against malaria in subjects who were exposed to Plasmodium falciparum parasites.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.